ISPOR Europe 2022 Home
  • About
    • News Center
  • Award Winners
  • Program
    • Program
      • Session
      • Paper
    • Learning Formats
    • Plenary Sessions
    • Spotlight Sessions
    • Posters
    • Educational Symposia & HEOR Theater
    • Program Committee
    • Speaker & Poster Presenter Resources
    • Student Program
  • Exhibits & Sponsorship
    • Sponsor List
    • Exhibitor List
    • Media Partners
  • Photo Gallery
large-circle

ISPOR Europe 2022

6 - 9 November

  • Home
  • Events
  • Past Conferences
  • ISPOR Europe 2022
  • Program
  • Program
  • Session

  • Cost-Effectiveness of Pembrolizumab+Lenvatinib for Treatment of Advanced Endometrial Carcinoma in Women Who Have Progressed Following Prior Systematic Therapy and Are Not Candidates for Curative Surgery or Radiation in France

    Nov 8, 2022, 15:00 PM
  • «
  • 761
  • 762
  • 763
  • 764
  • 765
  • 766
  • 767 (current)
  • 768
  • 769
  • 770
  • »
Quick Links
  • About
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal
  • Antitrust Compliance
  • Code of Ethics
  • Cookie Policy
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy
  • Terms and Conditions

Subscribe

Join ISPOR

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group